Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth B Hirsch

Showing results (31-40 of 74) with videos related to

Pageof 8
Sort By:
The Journal of Infectious Diseases|December 18, 2012
Assessment of antimicrobial combinations for Klebsiella pneumoniae carbapenemase-producing K. pneumoniaeElizabeth B Hirsch, Beining Guo, Kai-Tai Chang, et al.
Therapeutic Advances in Infectious Disease|June 19, 2023
Predictors of adverse safety events and unscheduled care among an outpatient parenteral antimicrobial therapy (OPAT) patient cohortKaylyn N Billmeyer, Jennifer K Ross, Elizabeth B Hirsch, et al.
Metabolomics : Official Journal of the Metabolomic Society|November 23, 2018
Volatile metabolic diversity of <i>Klebsiella pneumoniae</i> in nutrient-replete conditionsChristiaan A Rees, Katherine V Nordick, Flavio A Franchina, et al.
Microbiology Spectrum|June 28, 2024
Skipped wells and scientific error during fosfomycin agar dilution and broth microdilution lead to inconsistent minimal inhibitory concentrations and may be cause for reevaluating testing methods for <i>Klebsiella pneumoniae</i>Morgan L Bixby, Ellora C Daley, Lindsey B Collins, et al.
Antimicrobial Agents and Chemotherapy|April 25, 2012
In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteriaElizabeth B Hirsch, Kimberly R Ledesma, Kai-Tai Chang, et al.
Antimicrobial Agents and Chemotherapy|February 18, 2016
Susceptibility of Multidrug-Resistant Gram-Negative Urine Isolates to Oral AntibioticsElizabeth B Hirsch, Paola C Zucchi, Alice Chen, et al.
Journal of Bacteriology|April 13, 2022
The Atypical Antipsychotic Quetiapine Promotes Multiple Antibiotic Resistance in Escherichia coliYasuhiro Kyono, Lori Ellezian, YueYue Hu, et al.
The Journal of Antimicrobial Chemotherapy|March 6, 2018
Elucidation of the pharmacokinetic/pharmacodynamic determinants of fosfomycin activity against Pseudomonas aeruginosa using a dynamic in vitro modelHajira Bilal, Anton Y Peleg, Michelle P McIntosh, et al.
Jac-Antimicrobial Resistance|February 21, 2025
Heteroresistance associated with the production of fosfomycin-resistant inner colonies during disk diffusion testing among a geographically diverse collection of <i>Klebsiella pneumoniae</i> clinical isolatesMorgan L Bixby, Lindsey B Collins, Ellora C Daley, et al.
The Journal of Antimicrobial Chemotherapy|April 28, 2016
Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistanceClare C Walsh, Cornelia B Landersdorfer, Michelle P McIntosh, et al.
Pageof 8

Showing results (31-40 of 74) with videos related to

Sort By:
Pageof 8
The Journal of Infectious Diseases|December 18, 2012
Assessment of antimicrobial combinations for Klebsiella pneumoniae carbapenemase-producing K. pneumoniaeElizabeth B Hirsch, Beining Guo, Kai-Tai Chang, et al.
Therapeutic Advances in Infectious Disease|June 19, 2023
Predictors of adverse safety events and unscheduled care among an outpatient parenteral antimicrobial therapy (OPAT) patient cohortKaylyn N Billmeyer, Jennifer K Ross, Elizabeth B Hirsch, et al.
Metabolomics : Official Journal of the Metabolomic Society|November 23, 2018
Volatile metabolic diversity of <i>Klebsiella pneumoniae</i> in nutrient-replete conditionsChristiaan A Rees, Katherine V Nordick, Flavio A Franchina, et al.
Microbiology Spectrum|June 28, 2024
Skipped wells and scientific error during fosfomycin agar dilution and broth microdilution lead to inconsistent minimal inhibitory concentrations and may be cause for reevaluating testing methods for <i>Klebsiella pneumoniae</i>Morgan L Bixby, Ellora C Daley, Lindsey B Collins, et al.
Antimicrobial Agents and Chemotherapy|April 25, 2012
In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteriaElizabeth B Hirsch, Kimberly R Ledesma, Kai-Tai Chang, et al.
Antimicrobial Agents and Chemotherapy|February 18, 2016
Susceptibility of Multidrug-Resistant Gram-Negative Urine Isolates to Oral AntibioticsElizabeth B Hirsch, Paola C Zucchi, Alice Chen, et al.
Journal of Bacteriology|April 13, 2022
The Atypical Antipsychotic Quetiapine Promotes Multiple Antibiotic Resistance in Escherichia coliYasuhiro Kyono, Lori Ellezian, YueYue Hu, et al.
The Journal of Antimicrobial Chemotherapy|March 6, 2018
Elucidation of the pharmacokinetic/pharmacodynamic determinants of fosfomycin activity against Pseudomonas aeruginosa using a dynamic in vitro modelHajira Bilal, Anton Y Peleg, Michelle P McIntosh, et al.
Jac-Antimicrobial Resistance|February 21, 2025
Heteroresistance associated with the production of fosfomycin-resistant inner colonies during disk diffusion testing among a geographically diverse collection of <i>Klebsiella pneumoniae</i> clinical isolatesMorgan L Bixby, Lindsey B Collins, Ellora C Daley, et al.
The Journal of Antimicrobial Chemotherapy|April 28, 2016
Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistanceClare C Walsh, Cornelia B Landersdorfer, Michelle P McIntosh, et al.
Pageof 8